As development of a vaccine for COVID-19 continues to be a high a priority in the overall effort to control the pandemic, there are currently over a 100 potential vaccines in development. Although commercial availability of a vaccine is still realistically 12 to 18 months away, the “COVID-19 - Searching for Safe and Effective Vaccines” issues document was created to share any updates as they become available. Two of the most recent updates include preliminary phase I results for Inovio’s INO-4800 and phase I/II results from Pfizer/BioNTech’s BNT-162.
Although still in early phases, both updates show promising results and will continue to the next steps in their respective trials. Inovio plans to increase its phase I study to include patients over 50 years of age and is seeking regulatory clearance for phase 2/3 trials this summer. For Pfizer’s trial, the next step will be to monitor for safety and efficacy for six to 24 months for the 45 patients who were part of its phase I/II trials.
Download our "Coronavirus Disease 2019 (COVID-19) – Searching for Safe and Effective Vaccines” Issues Document below to learn more information regarding therapies in development for COVID-19.